메뉴 건너뛰기




Volumn 179, Issue 2, 2015, Pages 146-160

Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease

Author keywords

Dosing regimens; Immunoglobulin replacement therapy; Intravenous immunoglobulin; Primary immune deficiency disease; Subcutaneous immunoglobulin

Indexed keywords

IMMUNOGLOBULIN G;

EID: 84920263313     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12485     Document Type: Review
Times cited : (144)

References (101)
  • 1
    • 42049096072 scopus 로고    scopus 로고
    • Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency
    • Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am 2008; 28:413-437.
    • (2008) Immunol Allergy Clin North Am , vol.28 , pp. 413-437
    • Berger, M.1
  • 2
    • 48649085583 scopus 로고    scopus 로고
    • Common variable immunodeficiency: a new look at an old disease
    • Park MA, Li JT, Hagan JB, Maddox DE, Abraham RS. Common variable immunodeficiency: a new look at an old disease. Lancet 2008; 372:489-502.
    • (2008) Lancet , vol.372 , pp. 489-502
    • Park, M.A.1    Li, J.T.2    Hagan, J.B.3    Maddox, D.E.4    Abraham, R.S.5
  • 3
    • 84920273342 scopus 로고    scopus 로고
    • American Academy of Allergy Asthma and Immunology. Eight guiding principles for effective use of IVIG for patients with primary immunodeficiency. Milwaukee, WI, USA
    • American Academy of Allergy Asthma and Immunology. Eight guiding principles for effective use of IVIG for patients with primary immunodeficiency. Milwaukee, WI, USA, 2011.
    • (2011)
  • 4
    • 0034073949 scopus 로고    scopus 로고
    • The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy
    • Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000; 20:94-100.
    • (2000) J Clin Immunol , vol.20 , pp. 94-100
    • Chapel, H.M.1    Spickett, G.P.2    Ericson, D.3    Engl, W.4    Eibl, M.M.5    Bjorkander, J.6
  • 5
    • 34548665264 scopus 로고    scopus 로고
    • Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency
    • Fasth A, Nystrom J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatr 2007; 96:1474-1478.
    • (2007) Acta Paediatr , vol.96 , pp. 1474-1478
    • Fasth, A.1    Nystrom, J.2
  • 6
    • 0029908505 scopus 로고    scopus 로고
    • Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies
    • Abrahamsen TG, Sandersen H, Bustnes A. Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies. Pediatrics 1996; 98:1127-1131.
    • (1996) Pediatrics , vol.98 , pp. 1127-1131
    • Abrahamsen, T.G.1    Sandersen, H.2    Bustnes, A.3
  • 7
    • 0028857579 scopus 로고
    • Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs
    • Gardulf A, Andersen V, Bjorkander J etal. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995; 345:365-369.
    • (1995) Lancet , vol.345 , pp. 365-369
    • Gardulf, A.1    Andersen, V.2    Bjorkander, J.3
  • 8
    • 0036751568 scopus 로고    scopus 로고
    • Express subcutaneous IgG infusions: decreased time of delivery with maintained safety
    • Hansen S, Gustafson R, Smith CI, Gardulf A. Express subcutaneous IgG infusions: decreased time of delivery with maintained safety. Clin Immunol 2002; 104:237-241.
    • (2002) Clin Immunol , vol.104 , pp. 237-241
    • Hansen, S.1    Gustafson, R.2    Smith, C.I.3    Gardulf, A.4
  • 9
    • 0025738608 scopus 로고
    • Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion
    • Gardulf A, Hammarstrom L, Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 1991; 338:162-166.
    • (1991) Lancet , vol.338 , pp. 162-166
    • Gardulf, A.1    Hammarstrom, L.2    Smith, C.I.3
  • 10
    • 0020960844 scopus 로고
    • Slow subcutaneous immunoglobulin therapy in a patient with reactions to intramuscular immunoglobulin
    • Welch MJ, Stiehm ER. Slow subcutaneous immunoglobulin therapy in a patient with reactions to intramuscular immunoglobulin. J Clin Immunol 1983; 3:285-286.
    • (1983) J Clin Immunol , vol.3 , pp. 285-286
    • Welch, M.J.1    Stiehm, E.R.2
  • 11
    • 77957580751 scopus 로고    scopus 로고
    • Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency
    • Hagan JB, Fasano MB, Spector S etal. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol 2010; 30:734-745.
    • (2010) J Clin Immunol , vol.30 , pp. 734-745
    • Hagan, J.B.1    Fasano, M.B.2    Spector, S.3
  • 12
    • 80255138611 scopus 로고    scopus 로고
    • Efficacy and safety of subcutaneous Vivaglobin® replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study
    • Borte M, Quinti I, Soresina A etal. Efficacy and safety of subcutaneous Vivaglobin® replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study. J Clin Immunol 2011; 31:952-961.
    • (2011) J Clin Immunol , vol.31 , pp. 952-961
    • Borte, M.1    Quinti, I.2    Soresina, A.3
  • 13
    • 84920262371 scopus 로고    scopus 로고
    • International Patient Organisation for Primary Immunodeficiencies. IPOPI PID Patient Needs and Outlooks Survey. Cornwall, UK
    • International Patient Organisation for Primary Immunodeficiencies. IPOPI PID Patient Needs and Outlooks Survey. Cornwall, UK, 2012.
    • (2012)
  • 14
    • 80255127287 scopus 로고    scopus 로고
    • Subcutaneous immunoglobulin replacement therapy in infants and children with primary immunodeficiencies
    • Church JA, Howard V, Sleasman JW, Borte M, Berger M. Subcutaneous immunoglobulin replacement therapy in infants and children with primary immunodeficiencies. J Allergy Clin Immunol 2011; 127:AB213.
    • (2011) J Allergy Clin Immunol , vol.127 , pp. AB213
    • Church, J.A.1    Howard, V.2    Sleasman, J.W.3    Borte, M.4    Berger, M.5
  • 15
    • 77956615735 scopus 로고    scopus 로고
    • Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies
    • Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol 2010; 137:21-30.
    • (2010) Clin Immunol , vol.137 , pp. 21-30
    • Orange, J.S.1    Grossman, W.J.2    Navickis, R.J.3    Wilkes, M.M.4
  • 16
    • 84863599753 scopus 로고    scopus 로고
    • Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy
    • Orange JS, Belohradsky BH, Berger M etal. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol 2012; 169:172-181.
    • (2012) Clin Exp Immunol , vol.169 , pp. 172-181
    • Orange, J.S.1    Belohradsky, B.H.2    Berger, M.3
  • 17
    • 84888336146 scopus 로고    scopus 로고
    • Illustrative cases on individualizing immunoglobulin therapy in primary immunodeficiency disease
    • Bonagura VR. Illustrative cases on individualizing immunoglobulin therapy in primary immunodeficiency disease. Ann Allergy Asthma Immunol 2013; 111:S10-S13.
    • (2013) Ann Allergy Asthma Immunol , vol.111 , pp. S10-S13
    • Bonagura, V.R.1
  • 18
    • 77955266751 scopus 로고    scopus 로고
    • Association of FcRn expression with lung abnormalities and IVIG catabolism in patients with common variable immunodeficiency
    • Freiberger T, Grodecka L, Ravcukova B etal. Association of FcRn expression with lung abnormalities and IVIG catabolism in patients with common variable immunodeficiency. Clin Immunol 2010; 136:419-425.
    • (2010) Clin Immunol , vol.136 , pp. 419-425
    • Freiberger, T.1    Grodecka, L.2    Ravcukova, B.3
  • 19
    • 77952741985 scopus 로고    scopus 로고
    • Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years
    • Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010; 125:1354-1360.
    • (2010) J Allergy Clin Immunol , vol.125 , pp. 1354-1360
    • Lucas, M.1    Lee, M.2    Lortan, J.3    Lopez-Granados, E.4    Misbah, S.5    Chapel, H.6
  • 20
    • 46049100774 scopus 로고    scopus 로고
    • Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection
    • Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 2008; 122:210-212.
    • (2008) J Allergy Clin Immunol , vol.122 , pp. 210-212
    • Bonagura, V.R.1    Marchlewski, R.2    Cox, A.3    Rosenthal, D.W.4
  • 21
    • 4944262622 scopus 로고    scopus 로고
    • Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home
    • Gardulf A, Nicolay U, Math D etal. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004; 114:936-942.
    • (2004) J Allergy Clin Immunol , vol.114 , pp. 936-942
    • Gardulf, A.1    Nicolay, U.2    Math, D.3
  • 22
    • 1342333895 scopus 로고    scopus 로고
    • Pulmonary complications of primary immunodeficiencies
    • Buckley RH. Pulmonary complications of primary immunodeficiencies. Paediatr Respir Rev 2004; 5 (Suppl. A):S225-233.
    • (2004) Paediatr Respir Rev , vol.5 , pp. S225-S233
    • Buckley, R.H.1
  • 23
    • 37249071407 scopus 로고    scopus 로고
    • Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy
    • Gardulf A, Borte M, Ochs HD, Nicolay U. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. Clin Immunol 2008; 126:81-88.
    • (2008) Clin Immunol , vol.126 , pp. 81-88
    • Gardulf, A.1    Borte, M.2    Ochs, H.D.3    Nicolay, U.4
  • 24
    • 30944444864 scopus 로고    scopus 로고
    • Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home
    • Nicolay U, Kiessling P, Berger M etal. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 2006; 26:65-72.
    • (2006) J Clin Immunol , vol.26 , pp. 65-72
    • Nicolay, U.1    Kiessling, P.2    Berger, M.3
  • 25
    • 33750842089 scopus 로고    scopus 로고
    • Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies
    • Gardulf A, Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol 2006; 6:434-442.
    • (2006) Curr Opin Allergy Clin Immunol , vol.6 , pp. 434-442
    • Gardulf, A.1    Nicolay, U.2
  • 26
    • 0027180544 scopus 로고
    • The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions
    • Gardulf A, Bjorvell H, Gustafson R, Hammarstrom L, Smith CI. The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions. Clin Exp Immunol 1993; 92:200-204.
    • (1993) Clin Exp Immunol , vol.92 , pp. 200-204
    • Gardulf, A.1    Bjorvell, H.2    Gustafson, R.3    Hammarstrom, L.4    Smith, C.I.5
  • 27
    • 84883252281 scopus 로고    scopus 로고
    • Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review
    • Lingman-Framme J, Fasth A. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review. Drugs 2013; 73:1307-1319.
    • (2013) Drugs , vol.73 , pp. 1307-1319
    • Lingman-Framme, J.1    Fasth, A.2
  • 28
    • 46749117598 scopus 로고    scopus 로고
    • Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin
    • Fasth A, Nystrom J. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J Clin Immunol 2008; 28:370-378.
    • (2008) J Clin Immunol , vol.28 , pp. 370-378
    • Fasth, A.1    Nystrom, J.2
  • 29
    • 84860443133 scopus 로고    scopus 로고
    • Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases
    • Haddad E, Barnes D, Kafal A. Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases. Transfus Apher Sci 2012; 46:315-321.
    • (2012) Transfus Apher Sci , vol.46 , pp. 315-321
    • Haddad, E.1    Barnes, D.2    Kafal, A.3
  • 30
    • 84875701053 scopus 로고    scopus 로고
    • Controversies in IgG replacement therapy in patients with antibody deficiency diseases
    • Gelfand EW, Ochs HD, Shearer WT. Controversies in IgG replacement therapy in patients with antibody deficiency diseases. J Allergy Clin Immunol 2013; 131:1001-1005.
    • (2013) J Allergy Clin Immunol , vol.131 , pp. 1001-1005
    • Gelfand, E.W.1    Ochs, H.D.2    Shearer, W.T.3
  • 31
    • 84862865305 scopus 로고    scopus 로고
    • Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology
    • Orange JS, Ballow M, Stiehm ER etal. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 2012; 130:S1-24.
    • (2012) J Allergy Clin Immunol , vol.130 , pp. S1-24
    • Orange, J.S.1    Ballow, M.2    Stiehm, E.R.3
  • 32
    • 10744229712 scopus 로고    scopus 로고
    • Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial
    • Roifman CM, Schroeder H, Berger M etal. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol 2003; 3:1325-1333.
    • (2003) Int Immunopharmacol , vol.3 , pp. 1325-1333
    • Roifman, C.M.1    Schroeder, H.2    Berger, M.3
  • 33
    • 84885182424 scopus 로고    scopus 로고
    • Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in Argentina
    • Bezrodnik L, Gomez RA, Belardinelli G etal. Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in Argentina. J Clin Immunol 2013; 33:1216-1222.
    • (2013) J Clin Immunol , vol.33 , pp. 1216-1222
    • Bezrodnik, L.1    Gomez, R.A.2    Belardinelli, G.3
  • 34
    • 84866740512 scopus 로고    scopus 로고
    • Efficacy, safety and pharmacokinetics of a novel subcutaneous immunoglobulin, Evogam(R), in primary immunodeficiency
    • Empson MB, Tang ML, Pearce LK etal. Efficacy, safety and pharmacokinetics of a novel subcutaneous immunoglobulin, Evogam(R), in primary immunodeficiency. J Clin Immunol 2012; 32:897-906.
    • (2012) J Clin Immunol , vol.32 , pp. 897-906
    • Empson, M.B.1    Tang, M.L.2    Pearce, L.K.3
  • 35
    • 84861736225 scopus 로고    scopus 로고
    • Comparison of American and European practices in the management of patients with primary immunodeficiencies
    • Hernandez-Trujillo HS, Chapel H, Lo Re V III etal. Comparison of American and European practices in the management of patients with primary immunodeficiencies. Clin Exp Immunol 2012; 169:57-69.
    • (2012) Clin Exp Immunol , vol.169 , pp. 57-69
    • Hernandez-Trujillo, H.S.1    Chapel, H.2    Lo Re III, V.3
  • 36
    • 84901596592 scopus 로고    scopus 로고
    • Guidelines for the use of human immunoglobulin therapy in patients with primary immunodeficiencies in Latin America
    • Condino-Neto A, Costa-Carvalho BT, Grumach AS etal. Guidelines for the use of human immunoglobulin therapy in patients with primary immunodeficiencies in Latin America. Allergol Immunopathol (Madr) 2014; 42:245-260.
    • (2014) Allergol Immunopathol (Madr) , vol.42 , pp. 245-260
    • Condino-Neto, A.1    Costa-Carvalho, B.T.2    Grumach, A.S.3
  • 37
    • 84889878773 scopus 로고    scopus 로고
    • Subcutaneous immunoglobulin replacement therapy: the European experience
    • Chapel H, Gardulf A. Subcutaneous immunoglobulin replacement therapy: the European experience. Curr Opin Allergy Clin Immunol 2013; 13:623-629.
    • (2013) Curr Opin Allergy Clin Immunol , vol.13 , pp. 623-629
    • Chapel, H.1    Gardulf, A.2
  • 38
    • 80255138210 scopus 로고    scopus 로고
    • Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose
    • Berger M. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose. Curr Opin Allergy Clin Immunol 2011; 11:532-538.
    • (2011) Curr Opin Allergy Clin Immunol , vol.11 , pp. 532-538
    • Berger, M.1
  • 39
    • 84891719754 scopus 로고    scopus 로고
    • Pharmacokinetic modeling and simulation of biweekly subcutaneous immunoglobulin dosing in primary immunodeficiency
    • Landersdorfer CB, Bexon M, Edelman J etal. Pharmacokinetic modeling and simulation of biweekly subcutaneous immunoglobulin dosing in primary immunodeficiency. Postgrad Med 2013; 125:53-61.
    • (2013) Postgrad Med , vol.125 , pp. 53-61
    • Landersdorfer, C.B.1    Bexon, M.2    Edelman, J.3
  • 40
    • 53849119869 scopus 로고    scopus 로고
    • Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes
    • ix.
    • Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am 2008; 28:803-819. ix.
    • (2008) Immunol Allergy Clin North Am , vol.28 , pp. 803-819
    • Bonilla, F.A.1
  • 41
    • 0034020054 scopus 로고    scopus 로고
    • Lymphatic transport of proteins after subcutaneous administration
    • Porter CJ, Charman SA. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci 2000; 89:297-310.
    • (2000) J Pharm Sci , vol.89 , pp. 297-310
    • Porter, C.J.1    Charman, S.A.2
  • 42
    • 42049112189 scopus 로고    scopus 로고
    • Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies
    • Gustafson R, Gardulf A, Hansen S etal. Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies. Clin Exp Immunol 2008; 152:274-279.
    • (2008) Clin Exp Immunol , vol.152 , pp. 274-279
    • Gustafson, R.1    Gardulf, A.2    Hansen, S.3
  • 43
    • 80255138608 scopus 로고    scopus 로고
    • Efficacy and safety of Hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency
    • Borte M, Pac M, Serban M etal. Efficacy and safety of Hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency. J Clin Immunol 2011; 31:752-761.
    • (2011) J Clin Immunol , vol.31 , pp. 752-761
    • Borte, M.1    Pac, M.2    Serban, M.3
  • 44
    • 84920265424 scopus 로고    scopus 로고
    • Experience with a 20% subcutaneous immunoglobulin (Hizentra) in children with primary immunodeficiency diseases - a single-center review
    • Gregory R, Malcolmson C, Patel C, Woolley T, Jones A. Experience with a 20% subcutaneous immunoglobulin (Hizentra) in children with primary immunodeficiency diseases - a single-center review. J Allergy Clin Immunol 2013; 131:AB154.
    • (2013) J Allergy Clin Immunol , vol.131 , pp. AB154
    • Gregory, R.1    Malcolmson, C.2    Patel, C.3    Woolley, T.4    Jones, A.5
  • 45
    • 84920287183 scopus 로고    scopus 로고
    • Quantification of the wear-off effect towards the end of the intravenous immunoglobulin infusion interval: pooled data analysis
    • Lawo J-P, Hubsch A, Rojavin M. Quantification of the wear-off effect towards the end of the intravenous immunoglobulin infusion interval: pooled data analysis. J Allergy Clin Immunol 2014; 133:AB179.
    • (2014) J Allergy Clin Immunol , vol.133 , pp. AB179
    • Lawo, J.-P.1    Hubsch, A.2    Rojavin, M.3
  • 47
    • 82455163980 scopus 로고    scopus 로고
    • Subcutaneous immunoglobulin replacement therapy with Hizentra®, the first 20% SCIG preparation: a practical approach
    • Jolles S, Sleasman JW. Subcutaneous immunoglobulin replacement therapy with Hizentra®, the first 20% SCIG preparation: a practical approach. Adv Ther 2011; 28:521-533.
    • (2011) Adv Ther , vol.28 , pp. 521-533
    • Jolles, S.1    Sleasman, J.W.2
  • 48
    • 84920269771 scopus 로고    scopus 로고
    • New frontiers in subcutaneous immunoglobulin treatment
    • Jolles S, Stein MR, Longhurst HJ etal. New frontiers in subcutaneous immunoglobulin treatment. Biol Ther 2011; 1:3-18.
    • (2011) Biol Ther , vol.1 , pp. 3-18
    • Jolles, S.1    Stein, M.R.2    Longhurst, H.J.3
  • 49
    • 84880713148 scopus 로고    scopus 로고
    • Adverse effects of human immunoglobulin therapy
    • Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev 2013; 27:171-178.
    • (2013) Transfus Med Rev , vol.27 , pp. 171-178
    • Stiehm, E.R.1
  • 50
    • 84920282437 scopus 로고    scopus 로고
    • Immunologists' attitudes on 'wear-off' effects of IgG replacement therapy for primary immunodeficiency disease (PIDD) patients
    • Ballow M, Bullinger A, Murphy E, Berger M. Immunologists' attitudes on 'wear-off' effects of IgG replacement therapy for primary immunodeficiency disease (PIDD) patients. J Allergy Clin Immunol 2013; 131:AB156.
    • (2013) J Allergy Clin Immunol , vol.131 , pp. AB156
    • Ballow, M.1    Bullinger, A.2    Murphy, E.3    Berger, M.4
  • 51
    • 33645341439 scopus 로고    scopus 로고
    • Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology
    • Orange JS, Hossny EM, Weiler CR etal. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006; 117:S525-553.
    • (2006) J Allergy Clin Immunol , vol.117 , pp. S525-S553
    • Orange, J.S.1    Hossny, E.M.2    Weiler, C.R.3
  • 52
    • 17444424564 scopus 로고    scopus 로고
    • Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance
    • Hogy B, Keinecke HO, Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur J Health Econ 2005; 6:24-29.
    • (2005) Eur J Health Econ , vol.6 , pp. 24-29
    • Hogy, B.1    Keinecke, H.O.2    Borte, M.3
  • 53
    • 0029071368 scopus 로고
    • A comparison of the patient-borne costs of therapy with gamma globulin given at the hospital or at home
    • Gardulf A, Moller G, Jonsson E. A comparison of the patient-borne costs of therapy with gamma globulin given at the hospital or at home. Int J Technol Assess Health Care 1995; 11:345-353.
    • (1995) Int J Technol Assess Health Care , vol.11 , pp. 345-353
    • Gardulf, A.1    Moller, G.2    Jonsson, E.3
  • 54
    • 84873405539 scopus 로고    scopus 로고
    • Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center
    • Ducruet T, Levasseur MC, Des Roches A, Kafal A, Dicaire R, Haddad E. Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center. J Allergy Clin Immunol 2013; 131:585-587.
    • (2013) J Allergy Clin Immunol , vol.131 , pp. 585-587
    • Ducruet, T.1    Levasseur, M.C.2    Des Roches, A.3    Kafal, A.4    Dicaire, R.5    Haddad, E.6
  • 55
    • 84872681374 scopus 로고    scopus 로고
    • Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency
    • Martin A, Lavoie L, Goetghebeur M, Schellenberg R. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency. Transfus Med 2013; 23:55-60.
    • (2013) Transfus Med , vol.23 , pp. 55-60
    • Martin, A.1    Lavoie, L.2    Goetghebeur, M.3    Schellenberg, R.4
  • 56
    • 84920267477 scopus 로고    scopus 로고
    • Immune Deficiency Foundation. Treatment experiences and preferences of patients with primary immune deficiency diseases: first national survey. Towson, MD, USA
    • Immune Deficiency Foundation. Treatment experiences and preferences of patients with primary immune deficiency diseases: first national survey. Towson, MD, USA, 2003.
    • (2003)
  • 57
    • 84887011778 scopus 로고    scopus 로고
    • The variable in common variable immunodeficiency: a disease of complex phenotypes
    • Jolles S. The variable in common variable immunodeficiency: a disease of complex phenotypes. J Allergy Clin Immunol Pract 2013; 1:545-556.
    • (2013) J Allergy Clin Immunol Pract , vol.1 , pp. 545-556
    • Jolles, S.1
  • 58
    • 84920273827 scopus 로고    scopus 로고
    • The utility of anti-pneumococcal antibody measurement in patients with primary immunodeficiency receiving immunoglobulin
    • Jolles S, Heaps A, Moody M, Jones R. The utility of anti-pneumococcal antibody measurement in patients with primary immunodeficiency receiving immunoglobulin. J Allergy Clin Immunol 2014; 133:AB68.
    • (2014) J Allergy Clin Immunol , vol.133 , pp. AB68
    • Jolles, S.1    Heaps, A.2    Moody, M.3    Jones, R.4
  • 59
    • 0030793979 scopus 로고    scopus 로고
    • Human intravenous immunoglobulin in primary and secondary antibody deficiencies
    • Stiehm ER. Human intravenous immunoglobulin in primary and secondary antibody deficiencies. Pediatr Infect Dis J 1997; 16:696-707.
    • (1997) Pediatr Infect Dis J , vol.16 , pp. 696-707
    • Stiehm, E.R.1
  • 62
    • 0033511446 scopus 로고    scopus 로고
    • Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients
    • Quartier P, Debre M, De Blic J etal. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr 1999; 134:589-596.
    • (1999) J Pediatr , vol.134 , pp. 589-596
    • Quartier, P.1    Debre, M.2    De Blic, J.3
  • 63
    • 77950628870 scopus 로고    scopus 로고
    • Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology
    • Yong PL, Boyle J, Ballow M etal. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. Clin Immunol 2010; 135:255-263.
    • (2010) Clin Immunol , vol.135 , pp. 255-263
    • Yong, P.L.1    Boyle, J.2    Ballow, M.3
  • 64
    • 84920278833 scopus 로고    scopus 로고
    • Immune Deficiency Foundation. Primary immunodeficiency diseases in America: 2007 - the third national survey of patients. Towson, MD, USA
    • Immune Deficiency Foundation. Primary immunodeficiency diseases in America: 2007 - the third national survey of patients. Towson, MD, USA, 2009.
    • (2009)
  • 65
    • 0028173922 scopus 로고
    • Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency
    • Waniewski J, Gardulf A, Hammarstrom L. Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol 1994; 14:90-97.
    • (1994) J Clin Immunol , vol.14 , pp. 90-97
    • Waniewski, J.1    Gardulf, A.2    Hammarstrom, L.3
  • 66
    • 77953535202 scopus 로고    scopus 로고
    • Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis
    • Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immunol 2010; 30:301-307.
    • (2010) J Clin Immunol , vol.30 , pp. 301-307
    • Shapiro, R.1
  • 67
    • 84879551412 scopus 로고    scopus 로고
    • Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis
    • Shapiro RS. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis. Ann Allergy Asthma Immunol 2013; 111:51-55.
    • (2013) Ann Allergy Asthma Immunol , vol.111 , pp. 51-55
    • Shapiro, R.S.1
  • 68
    • 77954393427 scopus 로고    scopus 로고
    • Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency
    • Hoffmann F, Grimbacher B, Thiel J, Peter HH, Belohradsky BH. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. Eur J Med Res 2010; 15:238-245.
    • (2010) Eur J Med Res , vol.15 , pp. 238-245
    • Hoffmann, F.1    Grimbacher, B.2    Thiel, J.3    Peter, H.H.4    Belohradsky, B.H.5
  • 69
    • 33745040276 scopus 로고    scopus 로고
    • Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies - a prospective, multi-national study
    • Gardulf A, Nicolay U, Asensio O etal. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies - a prospective, multi-national study. J Clin Immunol 2006; 26:177-185.
    • (2006) J Clin Immunol , vol.26 , pp. 177-185
    • Gardulf, A.1    Nicolay, U.2    Asensio, O.3
  • 70
    • 84876439912 scopus 로고    scopus 로고
    • Home care use of intravenous and subcutaneous immunoglobulin for primary immunodeficiency in the United States
    • Huang F, Feuille E, Cunningham-Rundles C. Home care use of intravenous and subcutaneous immunoglobulin for primary immunodeficiency in the United States. J Clin Immunol 2013; 33:49-54.
    • (2013) J Clin Immunol , vol.33 , pp. 49-54
    • Huang, F.1    Feuille, E.2    Cunningham-Rundles, C.3
  • 71
    • 84920268263 scopus 로고    scopus 로고
    • Bioavailability of IgG administered by the subcutaneous route
    • Berger M, Jolles S, Sleasman JW. Bioavailability of IgG administered by the subcutaneous route. J Allergy Clin Immunol 2012; 129:AB114.
    • (2012) J Allergy Clin Immunol , vol.129 , pp. AB114
    • Berger, M.1    Jolles, S.2    Sleasman, J.W.3
  • 72
    • 77953292119 scopus 로고    scopus 로고
    • Tolerability of a new 10% liquid immunoglobulin for intravenous use, Privigen, at different infusion rates
    • Sleasman JW, Duff CM, Dunaway T, Rojavin MA, Stein MR. Tolerability of a new 10% liquid immunoglobulin for intravenous use, Privigen, at different infusion rates. J Clin Immunol 2010; 30:442-448.
    • (2010) J Clin Immunol , vol.30 , pp. 442-448
    • Sleasman, J.W.1    Duff, C.M.2    Dunaway, T.3    Rojavin, M.A.4    Stein, M.R.5
  • 73
    • 84920277941 scopus 로고    scopus 로고
    • ALPI-studien Att Leva med Primär Immunbrist Vuxenrapport. Rapport 1 [The SwePID study; to live with a primary immunodeficiency. Report regarding adults. Report 1/2007]. Stockholm: Karolinska Institutet
    • Gardulf A, Hansen S, Elnersson K etal. ALPI-studien Att Leva med Primär Immunbrist Vuxenrapport. Rapport 1 [The SwePID study; to live with a primary immunodeficiency. Report regarding adults. Report 1/2007]. Stockholm: Karolinska Institutet, 2007.
    • (2007)
    • Gardulf, A.1    Hansen, S.2    Elnersson, K.3
  • 74
    • 84920287577 scopus 로고    scopus 로고
    • Talecris Biotherapeutics, Inc., Research Triangle Park, NC: Grifols, USA.
    • Talecris Biotherapeutics, Inc., Research Triangle Park, NC: Grifols, USA.
  • 75
    • 84920262905 scopus 로고    scopus 로고
    • Baxter Healthcare Corporation, Westlake Village, CA, USA.
    • Baxter Healthcare Corporation, Westlake Village, CA, USA.
  • 76
    • 80052697929 scopus 로고    scopus 로고
    • Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases
    • Stein MR, Koterba A, Rodden L, Berger M. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases. Postgrad Med 2011; 123:186-193.
    • (2011) Postgrad Med , vol.123 , pp. 186-193
    • Stein, M.R.1    Koterba, A.2    Rodden, L.3    Berger, M.4
  • 77
    • 84880004959 scopus 로고    scopus 로고
    • Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push
    • Shapiro R. Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push. Clin Exp Immunol 2013; 173:365-371.
    • (2013) Clin Exp Immunol , vol.173 , pp. 365-371
    • Shapiro, R.1
  • 78
    • 0027438975 scopus 로고
    • Rapid subcutaneous immunoglobulin infusions in children
    • Thomas MJ, Brennan VM, Chapel HH. Rapid subcutaneous immunoglobulin infusions in children. Lancet 1993; 342:1432-1433.
    • (1993) Lancet , vol.342 , pp. 1432-1433
    • Thomas, M.J.1    Brennan, V.M.2    Chapel, H.H.3
  • 79
    • 68949119374 scopus 로고    scopus 로고
    • Efficacy and safety of Privigen in children and adolescents with primary immunodeficiency
    • Church JA, Borte M, Taki H etal. Efficacy and safety of Privigen in children and adolescents with primary immunodeficiency. Pediatr Asthma Allergy Immunol 2009; 22:53-62.
    • (2009) Pediatr Asthma Allergy Immunol , vol.22 , pp. 53-62
    • Church, J.A.1    Borte, M.2    Taki, H.3
  • 80
    • 0029681943 scopus 로고    scopus 로고
    • Treatment of hypogammaglobulinaemia with intravenous immunoglobulin, 1973-93
    • Skull S, Kemp A. Treatment of hypogammaglobulinaemia with intravenous immunoglobulin, 1973-93. Arch Dis Child 1996; 74:527-530.
    • (1996) Arch Dis Child , vol.74 , pp. 527-530
    • Skull, S.1    Kemp, A.2
  • 81
    • 84920263148 scopus 로고    scopus 로고
    • ALPI-studien Att Leva med Primär Immunbrist Föräldrarapport. Rapport 2 [The SwePID study; to live with a primary immunodeficiency. Report regarding parents]. Stockholm: Karolinska Institutet
    • Gardulf A, Hansen S, Elnersson K etal. ALPI-studien Att Leva med Primär Immunbrist Föräldrarapport. Rapport 2 [The SwePID study; to live with a primary immunodeficiency. Report regarding parents]. Stockholm: Karolinska Institutet, 2007.
    • (2007)
    • Gardulf, A.1    Hansen, S.2    Elnersson, K.3
  • 82
    • 84920272311 scopus 로고    scopus 로고
    • Use of subcutaneous IgG in patients on concomitant anticoagulant and antiplatelet therapy. Immunoglobulin Nursing Society National Conference, 3-5 August, 2012, Orlando, FL, USA. Conference Proceedings.
    • Stein MR, Farnan K, Eufrasio D etal. Use of subcutaneous IgG in patients on concomitant anticoagulant and antiplatelet therapy. Immunoglobulin Nursing Society National Conference, 3-5 August, 2012, Orlando, FL, USA. Conference Proceedings.
    • Stein, M.R.1    Farnan, K.2    Eufrasio, D.3
  • 83
    • 0035049375 scopus 로고    scopus 로고
    • Rapid subcutaneous IgG replacement therapy at home for pregnant immunodeficient women
    • Gardulf A, Andersson E, Lindqvist M, Hansen S, Gustafson R. Rapid subcutaneous IgG replacement therapy at home for pregnant immunodeficient women. J Clin Immunol 2001; 21:150-154.
    • (2001) J Clin Immunol , vol.21 , pp. 150-154
    • Gardulf, A.1    Andersson, E.2    Lindqvist, M.3    Hansen, S.4    Gustafson, R.5
  • 84
    • 84920268682 scopus 로고    scopus 로고
    • UK Department of Health. Clinical guidelines for immunoglobulin use: update to second edition. London, UK
    • UK Department of Health. Clinical guidelines for immunoglobulin use: update to second edition. London, UK, 2011.
    • (2011)
  • 85
    • 84872651749 scopus 로고    scopus 로고
    • Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics
    • Shapiro RS. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics. Pediatr Allergy Immunol 2013; 24:49-53.
    • (2013) Pediatr Allergy Immunol , vol.24 , pp. 49-53
    • Shapiro, R.S.1
  • 86
    • 84892752342 scopus 로고    scopus 로고
    • Importance of ancillary supplies for subcutaneous immunoglobulin infusion: management of the local infusion site
    • Duff C, Ochoa D, Riley P, Murphy E, Zampelli A. Importance of ancillary supplies for subcutaneous immunoglobulin infusion: management of the local infusion site. J Infus Nurs 2013; 36:384-390.
    • (2013) J Infus Nurs , vol.36 , pp. 384-390
    • Duff, C.1    Ochoa, D.2    Riley, P.3    Murphy, E.4    Zampelli, A.5
  • 87
    • 84920261645 scopus 로고    scopus 로고
    • American Academy of Allergy Asthma and Immunology. Guidelines for the site of care for administration of IGIV therapy. Milwaukee, WI
    • American Academy of Allergy Asthma and Immunology. Guidelines for the site of care for administration of IGIV therapy. Milwaukee, WI, 2011.
    • (2011)
  • 88
    • 0023735488 scopus 로고
    • Immunoglobulin replacement therapy by self-infusion at home
    • Chapel H, Brennan V, Delson E. Immunoglobulin replacement therapy by self-infusion at home. Clin Exp Immunol 1988; 73:160-162.
    • (1988) Clin Exp Immunol , vol.73 , pp. 160-162
    • Chapel, H.1    Brennan, V.2    Delson, E.3
  • 89
    • 0029303667 scopus 로고
    • Lifelong treatment with gammaglobulin for primary antibody deficiencies: the patients' experiences of subcutaneous self-infusions and home therapy
    • Gardulf A, Bjorvell H, Andersen V etal. Lifelong treatment with gammaglobulin for primary antibody deficiencies: the patients' experiences of subcutaneous self-infusions and home therapy. J Adv Nurs 1995; 21:917-927.
    • (1995) J Adv Nurs , vol.21 , pp. 917-927
    • Gardulf, A.1    Bjorvell, H.2    Andersen, V.3
  • 90
    • 34547893864 scopus 로고    scopus 로고
    • Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration
    • Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 2007; 4:427-440.
    • (2007) Expert Opin Drug Deliv , vol.4 , pp. 427-440
    • Frost, G.I.1
  • 91
    • 84869122138 scopus 로고    scopus 로고
    • Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency
    • Wasserman RL, Melamed I, Stein MR etal. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol 2012; 130:951-957.
    • (2012) J Allergy Clin Immunol , vol.130 , pp. 951-957
    • Wasserman, R.L.1    Melamed, I.2    Stein, M.R.3
  • 92
    • 84920278154 scopus 로고    scopus 로고
    • European Medicines Agency (EMA). HyQvia. Summary of product characteristics
    • European Medicines Agency (EMA). HyQvia. Summary of product characteristics, 2014.
    • (2014)
  • 93
    • 84920285871 scopus 로고    scopus 로고
    • HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] [package insert]. US License no. 140. Westlake Village, CA, USA: Baxter Healthcare Corporation
    • HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] [package insert]. US License no. 140. Westlake Village, CA, USA: Baxter Healthcare Corporation, 2014.
    • (2014)
  • 94
    • 34247279262 scopus 로고    scopus 로고
    • Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route
    • Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs 2007; 21:105-116.
    • (2007) BioDrugs , vol.21 , pp. 105-116
    • Gardulf, A.1
  • 95
    • 0141574289 scopus 로고    scopus 로고
    • Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy
    • Eijkhout HW, van den Broek PJ, van der Meer JW. Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy. Neth J Med 2003; 61:213-217.
    • (2003) Neth J Med , vol.61 , pp. 213-217
    • Eijkhout, H.W.1    van den Broek, P.J.2    van der Meer, J.W.3
  • 97
    • 0031802363 scopus 로고    scopus 로고
    • Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy
    • Sundin U, Nava S, Hammarstrom L. Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol 1998; 112:341-346.
    • (1998) Clin Exp Immunol , vol.112 , pp. 341-346
    • Sundin, U.1    Nava, S.2    Hammarstrom, L.3
  • 98
    • 84897027403 scopus 로고    scopus 로고
    • A 10% liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG
    • Lozano-Blasco J, Martin-Mateos MA, Alsina L etal. A 10% liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG. Allergol Immunopathol (Madr) 2012; 42:136-141.
    • (2012) Allergol Immunopathol (Madr) , vol.42 , pp. 136-141
    • Lozano-Blasco, J.1    Martin-Mateos, M.A.2    Alsina, L.3
  • 99
    • 67349234104 scopus 로고    scopus 로고
    • Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency
    • Wasserman RL, Church JA, Peter HH etal. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. Eur J Pharm Sci 2009; 37:272-278.
    • (2009) Eur J Pharm Sci , vol.37 , pp. 272-278
    • Wasserman, R.L.1    Church, J.A.2    Peter, H.H.3
  • 100
    • 79955837379 scopus 로고    scopus 로고
    • Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency
    • Wasserman RL, Melamed I, Nelson RP etal. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin Pharmacokinet 2011; 50:405-414.
    • (2011) Clin Pharmacokinet , vol.50 , pp. 405-414
    • Wasserman, R.L.1    Melamed, I.2    Nelson, R.P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.